Taiji Group Co., Ltd. (hereinafter referred to as "Taiji Group", stock code: 600129) was established in 1972 and completed its strategic restructuring in 2021, becoming a holding company of China Pharmaceutical Group Co., Ltd., the "Fortune 500" company. The company mainly focuses on intelligent manufacturing of modern Chinese medicine and supplemented by specialty chemical drugs. As an important part of the modern Chinese medicine sector of Sinopharm Group, it is committed to inheriting and innovating traditional Chinese medicine and developing modern medicine. It has 13 pharmaceutical factories and more than 20 pharmaceutical businesses. The company has more than 3,000 chain pharmacies with Sichuan and Chongqing as its main base, covering pharmaceutical research and development, pharmaceutical production, pharmaceutical commerce, Chinese medicinal materials resources and other fields, with 13,000 employees.

In 1998, Taiji Group cooperated with many domestic and foreign institutions to establish a national postdoctoral workstation; in 1999, Taiji Group Technology Center was recognized as a National Enterprise Technology Center. In recent years, it has undertaken nearly 40 major special projects such as the Ministry of Science and Technology, the National Development and Reform Commission, and the Ministry of Industry and Information Technology, and more than 50 provincial projects. The company has successfully developed more than 40 new drugs, won more than 30 national new drug certificates, and won three Chinese patent gold medals. It has 300 valid authorized patents, a total of 1,240 drug approval documents, including 690 Chinese medicine varieties, 550 chemical medicine varieties, 739 medical insurance varieties, and 369 basic drugs.

The company's products cover six major therapeutic areas, mainly including digestive system and metabolic drugs represented by Huoxiang Zhengqi Oral Liquid, Tailuo, etc., respiratory system drugs represented by acute syrup, and cardiovascular drugs represented by Salvia miltiorrhiza oral Liquid. , anti-infective drugs represented by Yibao Shiling, nervous system drugs represented by Tongtian Oral Liquid and Mefikang, anti-tumor and immunomodulatory drugs represented by paclitaxel, Bushen Yishou Capsules, etc., and Big Health Health products. The company's products have a high market share, and its brand and quality have won the recognition and trust of the people.

Taiji Group will adhere to the corporate philosophy of "caring for life and caring for health", with the original mission of "Chinese Medicine Conservation in China, Taiji Helps the people", follow the goal positioning of "making the main business of medical and health stronger, better and bigger", and produce new sources, We will strive for excellence, continuously promote the modernization of traditional Chinese medicine, strive to build a world-class traditional Chinese medicine enterprise, promote traditional Chinese medicine to the world, and contribute the power of Chinese medicine Tai Chi to build a healthy China and realize the Chinese dream of the great rejuvenation of the Chinese nation.